Clinical trials: Immune Deficiency Disorders
Human Immunodeficiency Virus, Pre-Exposure Prophylaxis
Universal Test and Connect for HIV Service Delivery in South Africa
The goal of this study is to determine how many patients with HIV or at high risk of getting HIV attend the Emergency Department (ED) in South Africa (SA).
- Conditions
- Human Immunodeficiency Virus, Pre-Exposure Prophylaxis, Emergency Department, South Africa
- Trial name
- UTC: SA (NCT06408142)
- Testing
- HIV testing, In-depth interview
- Where
- South Africa
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV/AIDS
A Cluster Randomised Trial of Community-led Distribution of HIV Self-tests in Rural Malawi (HIV Self-Testing Africa [STAR])
The aim of this study is to determine the benefits, costs and safety of community-led delivery of HIV self-testing (HIVST) kits in rural Malawi, with a focus on testing and linkage to care and prevention services among defined…
- Trial name
- NCT03541382
- Testing
- OraQuick® HIV Self-Test
- Where
- Malawi
- Volunteers
- 7,880 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Immune Deficiency, Immune Dysregulation Disorder
Allergy and Immunology Natural History Study
This protocol is a natural history study designed to evaluate subjects (and some family members) with suspected or identified genetic diseases of allergic inflammation or Immune Dysregulation.
- Conditions
- Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
- Trial name
- NCT05584488
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV, AIDS
Bioequivalence Study of Pediatric Formulations to Treat HIV Infection
The purpose of the study is to determine the bioavailability/bioequivalence of two pediatric formulations (tablet and reconstitutable suspension) of lamivudine/zidovudine/ nevirapine in comparison to an innovator product.
- Trial name
- NCT01469520
- Testing
- Epivir®, Retrovir® and Viramune®, Lamivudine, Zidovudine and nevirapine, Lamivudine, zidovudine, nevirapine
- Where
- Nigeria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Elim Pediatric Pharmaceuticals Inc.
HIV/AIDS and Infections
Evaluating a Microfinance Intervention for Vulnerable Women in Kazakhstan
This study will examine the efficacy of a combined HIV and microfinance intervention to reduce biologically confirmed sexually transmitted infections (STIs), and new incidence of HIV and HCV, as well as reported sexual and drug…
- Trial name
- MFKZ (NCT02406482)
- Testing
- Microfinance intervention (MF), HIV risk reduction (HIVRR)
- Where
- 3 sites in Kazakhstan
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Pre-exposure prophylaxis (PrEP) is an HIV prevention strategy in which HIV medicines are used by a person before they are exposed to HIV in order to decrease his or her chance of getting infected.
- Trial name
- MVC-PREP (NCT01749566)
- Testing
- maraviroc
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Emory University
Hereditary Angioedema
An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
This is an open-label, single sequence study to evaluate the effect of BCX7353 on hepatic and intestinal cytochrome P450 enzymes using probe substrate drugs in healthy subjects.
- Trial name
- NCT02819102
- Testing
- BCX7353 and probes
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
HIV Infection
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)
As a measure of secondary prophylaxis, and with the final objective of avoiding the infection, it has been suggested to use antiretroviral therapy. This is known as post-exposure prophylaxis (PEP).
- Trial name
- NCT01533272
- Testing
- Tenofovir, emtricitabine, maraviroc, Tenofovir, emtricitabine, lopinavir/r
- Where
- Spain
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
HIV/AIDS, Tuberculosis
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load
The standard treatment for TB consists of rifampicin (RIF) as part of the regimen. However, due to drug-drug interactions (DDI), the bioavailability of PIs is greatly reduced when co-administered with RIF necessitating use of…
- Trial name
- DERIVE (NCT04121195)
- Testing
- Dose escalation
- Where
- Uganda
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
HIV Infections, AIDS
Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission
The purposes of this study are to determine whether Carraguard® Gel can prevent the transmission of HIV when used during vaginal intercourse, and to confirm that the gel is safe for vaginal use.
- Conditions
- HIV Infections, AIDS, Sexually Transmitted Diseases, HIV Seroconversion
- Trial name
- NCT00213083
- Testing
- Carraguard (PC-515)
- Where
- 3 sites in South Africa
- Volunteers
- 6,203 people, healthy volunteers welcome
- Sponsor
- Population Council
Tuberculosis, Pulmonary, HIV Coinfection
Pharmacist-Led Intervention to Improve TB Treatment Adherence
The goal of this clinical trial is to compare the adherence of co-morbid patients in control and experimental group The main question[s]it aims to answer are: 1.
- Trial name
- RA-15041995 (NCT06608069)
- Testing
- Educational counselling
- Where
- 2 sites in Malaysia
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
HIV Infections
Durability of Adherence in Self-Management of HIV
Adherence to highly active antiretroviral therapy (HAART) is critical to successful treatment of HIV. This study tested an intervention that helps people infected with HIV take all their medications when and how they were…
- Trial name
- DASH (NCT00991302)
- Testing
- CAP-IT
- Where
- 2 sites in United States, Peru
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
Optimizing Implementation of Long Acting Injectable PrEP
Our goal is to optimize LAI-PrEP implementation within the context of other PrEP methods. Our strategy is flexible to allow pivot to include forthcoming PrEP dosing options should they become available
- Trial name
- NCT07649551
- Testing
- Plan-Do-Study-Act
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
HIV/AIDS, Periodontal Diseases
Effects of Periodontal Treatment on HIV-infected Patients
Periodontal diseases, such as chronic periodontitis (CP), frequently occur in immunosuppressed patients, including HIV-infected patients.
- Trial name
- NCT03262402
- Testing
- Basic periodontal treatment
- Where
- Brazil
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
HIV (Human Immunodeficiency Virus)
Improving Access to HIV Testing for Children in Uganda
The goal of this study is to learn if HIV screening testing can be done for children ages 18 months to 5 years by traditional healers in Southwestern Uganda.
- Trial name
- NCT07236905
- Testing
- HIV saliva swab screening test, Referral for HIV testing
- Where
- Uganda
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
COVID-19, SARS-CoV-2
Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)
The primary objective is to assess the safety and tolerability of samRNA vaccines GRT-R912, GRT-R914, and GRT-R918 when administered as prime and/or boost in healthy adult participants naïve to severe acute respiratory syndrome…
- Trial name
- NCT05435027
- Testing
- GRT-R912, samRNA-Spikebeta-TCE11, GRT-R914, samRNA-Spikebeta-TCE9, GRT-R918, samRNA-SpikeOmicron-N-TCE11
- Where
- 4 sites in South Africa
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Gritstone bio, Inc.
Vitamin D Deficiency
Treatment Study of Vitamin D Deficiency in Adolescents
To compare the efficacy of two high dose vitamin D3 regimens (5,000 IU daily vs. 50,000 IU weekly) used clinically for the treatment of vitamin D deficiency versus a low dose of vitamin D3 used for supplementation (1,000 IU…
- Trial name
- NCT01784029
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
HIV Infections
Rapid HIV Testing for Emergency Department Patients
The purpose of this study is to test data collection options in emergency departments (EDs) and to enhance ED patient awareness of the risk of HIV infection.
- Trial name
- NCT00676481
- Testing
- HIV risk education
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-infection
Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV
The purpose of this study is to see if individuals with HIV-infection, particularly those with increased belly fat, have abnormalities in the renin angiotensin aldosterone axis.
- Trial name
- NCT01407237
- Testing
- Angiotensin II Infusion
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Background: HIV stands for human immunodeficiency virus, which is the virus that causes AIDS. There is currently no licensed vaccine to prevent HIV infection.
- Trial name
- NCT03783130
- Testing
- VRC-HIVRGP096-00-VP, Alum Adjuvant
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)